MQCC confirms microarray reliability
This article was originally published in The Gray Sheet
Executive Summary
First report of the Microarray Quality Control Consortium, published in the Sept. 8 Nature Biotechnology, concludes that under the appropriate circumstances, "microarray data can indeed be reproducible and comparable among different formats and laboratories." The consortium, spearheaded by FDA scientists, assessed the performance of seven microarray platforms in profiling RNA expression. Published reports question the reliability of the tests, which are used to detect the cellular activity of DNA and RNA. FDA's National Center for Toxicological Research will hold a meeting on microarrays in Jefferson, Ark. on Sept. 21...
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.